New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
12:14 EDTABMDAbiomed says DOJ closes investigation into Impella 2.5
Abiomed announced that it has received confirmation from the United States Department of Justice that it has closed its investigation into the company’s marketing of the Impella 2.5 device without taking enforcement action. “We are pleased that the Department of Justice has chosen to close its investigation without pursuing any further action and that this matter is now behind us. We have always remained steadfast in our integrity and our commitment to putting our patients first,” said Abiomed CEO Michael Minogue.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use